Condition (MeSH)
Disease Resistance
ClinicalTrials.gov lists 5 trials for Disease Resistance or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
5 of the 5 trials are tagged with Disease Resistance itself; the rest are tagged with a narrower condition beneath it.
When did Disease Resistance trials start? (5)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Not applicable
- Observational
Top of scale: 1
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Disease Resistance trials in? (2)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Not applicable | 3 |
| Observational | 2 |
How many Disease Resistance trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 2 |
| Unknown status | 2 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which publications cover Disease Resistance? (28)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The role of host genetics in the immune response to SARS-CoV-2 and COVID-19 susceptibility and severity. | Immunological reviews | 2020 | Yes |
| Transcriptomic profile change, immunological response and disease resistance of Oreochromis niloticus fed with conventional and Nano-Zinc oxide dietary supplements. | Fish & shellfish immunology | 2019 | Yes |
| Antiviral Defense and Innate Immune Memory in the Oyster. | Viruses | 2018 | Yes |
| Host defenses against metabolic endotoxaemia and their impact on lipopolysaccharide detection. | International reviews of immunology | 2017 | Yes |
| Beneficial Microbes: The pharmacy in the gut. | Bioengineered | 2016 | Yes |
Showing 5 of 28 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.